Vista Pharmaceuticals Intrinsic Value
Vista Pharmaceuticals (VISTAPH) median intrinsic value is ₹19.30 from 2 valuation models (range ₹15–₹19), vs current price ₹7.72 — +150.0% upside (Trading Below Calculated Value), margin of safety 60.0%. Browse VISTAPH complete financial statements for revenue, profit, balance sheet and cash flow data.
VISTAPH Valuation Methods Summary — DCF, Graham Number & P/E
Vista Pharmaceuticals intrinsic value across 2 models vs current price ₹7.72 — upside/downside and value range per method. Also explore VISTAPH share price history to track price trends across different timeframes.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹19.30 | ₹17.37 - ₹21.23 | +150.0% | Book Value/Share: ₹37.50, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹15.00 | ₹13.50 - ₹16.50 | +94.3% | Revenue/Share: ₹7.50, P/S: 2.0x |
VISTAPH Intrinsic Value vs Market Price — All Valuation Models
Vista Pharmaceuticals fair value range ₹15–₹19 vs current market price ₹7.72 across 2 valuation models. For current market price and key ratios, visit Vista Pharmaceuticals share price chart.
VISTAPH Intrinsic Value Analysis — Undervalued or Overvalued?
Vista Pharmaceuticals median intrinsic value ₹19.30, current price ₹7.72 — Trading Below Calculated Value by 150.0%, margin of safety 60.0%.
What is the intrinsic value of VISTAPH?
Based on our comprehensive analysis using 2 different valuation methods, the estimated intrinsic value of Vista Pharmaceuticals (VISTAPH) is ₹19.30 (median value). With the current market price of ₹7.72, this represents a +150.0% variance from our estimated fair value.
The valuation range spans from ₹15.00 to ₹19.30, indicating ₹15.00 - ₹19.30.
Is VISTAPH undervalued or overvalued?
Based on our multi-method analysis, Vista Pharmaceuticals (VISTAPH) appears to be trading below calculated value by approximately 150.0%.
VISTAPH Financial Health — Key Ratios vs Industry Benchmarks
Vista Pharmaceuticals financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 8.33 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | -17.8% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | -115.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.15x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
VISTAPH Cash Flow Quality — Operating & Free Cash Flow
Vista Pharmaceuticals operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-7 Cr | ₹-7 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹-5 Cr | ₹-6 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹-2 Cr | ₹-3 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹-1 Cr | ₹-1 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹-7 Cr | ₹-7 Cr | Negative Cash Flow | 3/10 |